Compare BY & GLUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BY | GLUE |
|---|---|---|
| Founded | 1914 | 2019 |
| Country | United States | United States |
| Employees | N/A | 147 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.4B |
| IPO Year | 2017 | 2021 |
| Metric | BY | GLUE |
|---|---|---|
| Price | $32.51 | $18.56 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $33.50 | $29.50 |
| AVG Volume (30 Days) | 157.7K | ★ 912.4K |
| Earning Date | 04-22-2026 | 01-01-0001 |
| Dividend Yield | ★ 1.51% | N/A |
| EPS Growth | ★ 3.00 | N/A |
| EPS | ★ 2.12 | N/A |
| Revenue | N/A | ★ $75,622,000.00 |
| Revenue This Year | $17.06 | $84.02 |
| Revenue Next Year | $2.84 | N/A |
| P/E Ratio | ★ $15.27 | $72.42 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $22.63 | $3.50 |
| 52 Week High | $33.89 | $25.77 |
| Indicator | BY | GLUE |
|---|---|---|
| Relative Strength Index (RSI) | 54.16 | 44.19 |
| Support Level | $32.00 | $17.68 |
| Resistance Level | $33.89 | $18.66 |
| Average True Range (ATR) | 0.83 | 1.09 |
| MACD | -0.18 | -0.10 |
| Stochastic Oscillator | 43.46 | 35.16 |
Byline Bancorp Inc is the holding company for Byline Bank, a full-service commercial bank serving small-and-medium sized businesses, financial sponsors, and consumers. The company offers a broad range of banking products and services to small and medium sized businesses, commercial real estate and online account opening to consumer and business. Also provide trust and wealth management services to its customers. In addition to traditional commercial banking business, company provide small ticket equipment leasing solutions through Byline Financial Group, a wholly-owned subsidiary of Byline Bank.
Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.